Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04582903
Recruitment Status : Recruiting
First Posted : October 12, 2020
Last Update Posted : November 26, 2020
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) )

Brief Summary:

Background:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). The global outbreak of COVID-19 is a major public health problem. COVID-19 causes a wide range of symptoms. These symptoms range from mild breathing problems to life-threatening problems or death. Some people have no symptoms. This study aims to learn how acute and late immune responses to COVID-19 lead to different outcomes. The immune system is the body s defense against germs, including viruses, that invade the body.

Objective:

To characterize the immune responses during and after SARS-CoV-2 infection and determine if there is any relationship to clinical course and outcome.

Eligibility:

People ages 0 99 who have confirmed or suspected SARS-CoV-2 infection, people who are not infected despite heavy exposure, and relatives of enrolled participants.

Design:

This is a sample collection protocol to receive send-in biological specimens for exploratory studies, including gene testing. Participants will not be seen at the NIH for study visits.

Study staff will talk with participants health care providers to screen them for the study. Participants enrolled into the protocol will send samples and clinical information at least once and more often if the participant has COVID-19. All participants will provide blood samples and possibly stool. We may also ask for left over specimens from any medical procedures completed as part of medical care. The study staff will also request participants health care providers to complete a survey to collect demographic and medical data. Some of this information may need to be provided directly by the participant.

Pregnant individuals are invited to participate and may be asked to give cord blood samples after delivery. Study findings that affect participants health may be shared with their health care provider. Depending on findings, participants may be contacted to take part in other NIH studies.

...


Condition or disease
COVID-19 Infection

Detailed Description:
In response to the public health emergency posed by the coronavirus disease 2019 (COVID-19) pandemic, researchers at the National Institute of Allergy and Infectious Diseases (NIAID) are leading a large international collaboration to characterize the innate and adaptive immune responses to acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and convalescence. This protocol will allow the NIAID Laboratory of Clinical Immunology and Microbiology (LCIM) to remotely enroll participants for send-in sample collection for analyses to characterize the immune response to SARS-CoV-2, better enabling the LCIM to support NIAID s commitment to safeguarding the health of Americans and people around the world by accelerating research efforts to characterize SARS CoV 2. This is a prospective sample collection protocol to receive send in biological samples (e.g., blood, saliva, stool, and leftover clinically collected samples) for exploratory studies to characterize the immune response to COVID 19. Participants will not be seen at the NIH for study visits. Under this protocol, samples will be collected longitudinally from up to 300 patients with confirmed or suspected SARS CoV 2 infection and sent to the NIH for research evaluations. Additionally, samples will be collected from up to 200 uninfected patients and patient relatives. Testing will be performed to improve understanding of host immune responses to COVID-19, including but not limited to genetic, molecular, and proteomic testing. Findings relevant to participants health and medical care may be returned to them and their referring health care providers or study teams.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 500 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Send-in Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence
Estimated Study Start Date : December 1, 2020
Estimated Primary Completion Date : August 31, 2025
Estimated Study Completion Date : August 31, 2025

Resource links provided by the National Library of Medicine


Group/Cohort
Biological Relative
Biological relative of a participant being studied under this protocol. Relatives may be biological mother, father, siblings, children, grandparents, aunts, uncles, or first cousins
Confirmed or Suspected SARS-CoV-2 infection
Patient with a known or suspected diagnosis of SARS-CoV-2 infection (past or current),typically but not always supported by a positive PCR test for viral RNA
Exposed but Uninfected
Individual who has remained uninfected with negative SARS-CoV-2 serologies despite heavyor extensive COVID-19 exposure in the workplace or home environment



Primary Outcome Measures :
  1. Characterization of the dynamic changes of innate and adaptive immune responses during SARS CoV 2 infection and convalescence. [ Time Frame: End of Study ]
    These endpoints were chosen to provide in depth molecularmeasurements of a wide variety of innate and adaptive host immuneresponses to a novel pathogen in heterogenous patients. This is anexploratory hypothesis generating study to identify findings for validation in future studies. These endpoints are needed to better understand pathogenic mechanisms, improve prognostic tools, optimize existing therapies, and identify new targets for treatment.

  2. Identification of genetic variants that are associated with either severe/lethal COVID-19 or resistance to SARS CoV 2 infection. [ Time Frame: End of Study ]
    These endpoints were chosen to provide in depth molecularmeasurements of a wide variety of innate and adaptive host immuneresponses to a novel pathogen in heterogenous patients. This is anexploratory hypothesis generating study to identify findings for validation in future studies. These endpoints are needed tobetter understand pathogenic mechanisms, improve prognostic tools, optimize existing therapies, and identify new targets for treatment.

  3. Measurement of proinflammatory/anti inflammatory cytokines produced during SARS CoV 2 infection and convalescence, including the IFN signature response. [ Time Frame: End of Study ]
    These endpoints were chosen to provide in depth molecular measurements of a wide variety of innate and adaptive host immuneresponses to a novel pathogen in heterogenous patients. This is anexploratory hypothesis generating study to identify findings for validation in future studies. These endpoints are needed to better understand pathogenic mechanisms, improve prognostic tools, optimize existing therapies, and identify new targets for treatment.

  4. Survey of other potential blood proteomic biomarkers of disease. [ Time Frame: End of Study ]
    These endpoints were chosen to provide in depth molecular measurements of a wide variety of innate and adaptive host immuneresponses to a novel pathogen in heterogenous patients. This is anexploratory hypothesis generating study to identify findings for validation in future studies. These endpoints are needed to better understand pathogenic mechanisms, improve prognostic tools, optimize existing therapies, and identify new targets for treatment.

  5. Characterization of serological responses against SARS CoV 2, other viruses or microbiota, and host antigens. [ Time Frame: End of Study ]
    These endpoints were chosen to provide in depth molecular measurements of a wide variety of innate and adaptive host immuneresponses to a novel pathogen in heterogenous patients. This is anexploratory hypothesis generating study to identify findings for validation in future studies. These endpoints are needed to better understand pathogenic mechanisms, improve prognostic tools, optimize existing therapies, and identify new targets for treatment.

  6. Characterization of intrapatient SARS-CoV-2 genetic variation andevolution during infection and convalescence. [ Time Frame: End of Study ]
    These endpoints were chosen to provide in depth molecular measurements of a wide variety of innate and adaptive host immuneresponses to a novel pathogen in heterogenous patients. This is anexploratory hypothesis generating study to identify findings for validation in future studies. These endpoints are needed to better understand pathogenic mechanisms, improve prognostic tools, optimize existing therapies, and identify new targets for treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 99 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
We plan to enroll up to 500 total participants in this protocol, including up to 300 patients with SARS-CoV-2 infection and 200 other participants (patient relatives and individuals who remain uninfected despite heavy or extensive COVID-19 exposure in the workplace or home environment). Health care providers worldwide will contact the study staff to request enrollment of patients and/or their relatives. Additionally, investigators may refer patients from other clinical studies.
Criteria
  • INCLUSION CRITERIA:

Participants enrolled onto this protocol must meet all of the following criteria:

  1. Aged 0-99 years (including viable neonates).
  2. Meets one of the following criteria:

    1. Patient with a known or suspected diagnosis of SARS-CoV-2 infection (past or current), typically but not always supported by a positive PCR test for viral RNA;
    2. Individual who has remained uninfected with negative SARS-CoV-2 serologies despite heavy or extensive COVID-19 exposure in the workplace or home environment; or
    3. Biological relative of a participant being studied under this protocol. Relatives may be biological mother, father, siblings, children, grandparents, aunts, uncles, or first cousins.
  3. For individuals considered for enrollment as uninfected individuals and biological relatives, able to provide informed consent.
  4. Willing to allow genetic testing.
  5. Willing to allow storage of samples and data for future research.

EXCLUSION CRITERIA:

Individuals meeting any of the following criteria will be excluded from study participation:

1. Any condition that, in the opinion of the investigator, contraindicates participation in this study.

Since patients can be concurrently infected with multiple respiratory viruses, positive testing for other viruses such as rhinovirus, influenza virus, etc., does not exclude an individual from study participation where there remains a high clinical suspicion of COVID-19 infection despite negative testing for SARS-CoV-2.

Co-enrollment guidelines: Participants may be co-enrolled in other studies; however, study staff should be notified of co-enrollment.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04582903


Contacts
Layout table for location contacts
Contact: Sandra M Maxwell, R.N. (240) 627-3078 maxwells@mail.nih.gov

Locations
Layout table for location information
United States, Maryland
Niaid/Lcim Recruiting
Rockville, Maryland, United States, 20892
Contact: Helen Su, M.D. Ph. D    301-451-8783    hsu@niaid.nih.gov   
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
Layout table for investigator information
Principal Investigator: Helen C Su, M.D. National Institute of Allergy and Infectious Diseases (NIAID)
Publications:
Layout table for additonal information
Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT04582903    
Other Study ID Numbers: 10000044
000044-I
First Posted: October 12, 2020    Key Record Dates
Last Update Posted: November 26, 2020
Last Verified: November 23, 2020
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) ):
Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2)
Repository
Pandemic
Genetics
Proteomics
Additional relevant MeSH terms:
Layout table for MeSH terms
Convalescence
Disease Attributes
Pathologic Processes